GlassScriptPhysician profile
Jawad Agha
NPI 1235164872
$3,803.27
in general payments reported to CMS, 2019-2025
24 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $262 · 2023: $570 · 2024: $1,028 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $607.78 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $484.75 | 2021-2025 | Vraylar |
| Alkermes, INC. | $455.80 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $445.12 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $376.79 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $220.81 | 2024-2025 | Symbravo, Auvelity |
| Pfizer INC. | $169.26 | 2023-2025 | |
| Glaxosmithkline, LLC. | $154.40 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $123.31 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lundbeck LLC | $121.19 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $116.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.97 | 2022-2024 | Jardiance |
| Corcept Therapeutics | $79.63 | 2025 | Korlym |
| Abbott Laboratories | $63.66 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $55.59 | 2023-2024 | Repatha, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.85 | 2022-2023 | Tepezza |
| Lilly USA, LLC | $48.01 | 2023 | Mounjaro, Trulicity |
| Orexo US, INC. | $43.58 | 2025 | Zubsolv |
| Hologic Sales and Service, LLC | $23.00 | 2025 | Aptima |
| Boston Scientific Corporation | $17.71 | 2025 | Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2025 | Zoryve |
| Supernus Pharmaceuticals, INC. | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.